RT Journal Article ID 292bed023d1be09f A1 Bajek, Anna A1 Porowinska, Dorota A1 Kloskowski, Tomasz A1 Brzoska, Edyta A1 Ciemerych, Maria A. A1 Drewa, Tomasz T1 Cell Therapy in Duchenne Muscular Dystrophy Treatment: Clinical Trials Overview JF Critical Reviews™ in Eukaryotic Gene Expression JO CRE YR 2015 FD 2015-03-12 VO 25 IS 1 SP 1 OP 11 K1 Duchenne muscular dystrophy K1 DMD K1 cell therapies K1 myoblast transplantation K1 muscle regeneration K1 stem cells AB Duchenne muscular dystrophy (DMD), the most common and most severe form of all muscular dystrophies, leads to progressive muscle fiber necrosis, fibroblast proliferation, and growth of fibrous tissue and fat. The most common cause of death in DMD patients is cardiac and respiratory failure. Current pharmacological and other treatment methods do not lead to full recovery. For this reason, new alternatives for skeletal muscle regeneration are being investigated. Transplantation of myoblasts from healthy donors is one studied approach to muscle treatment in DMD patients. However, the results of intramuscular injection of in vitro cultured myoblasts are still not satisfactory. The use of autologous stem cells is also proposed. Despite many ongoing studies, this therapy is still in preliminary testing and requires more experiments. PB Begell House LK https://www.dl.begellhouse.com/journals/6dbf508d3b17c437,4abcfae40adc6398,292bed023d1be09f.html